Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis

Arthritis Res Ther. 2018 Jun 8;20(1):122. doi: 10.1186/s13075-018-1628-6.

Abstract

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC), registered 22 October 2009, NCT01000441.

Keywords: Biologic agents; Interleukin 33; Personalized medicine; Rheumatoid arthritis.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept / therapeutic use
  • Adalimumab / therapeutic use
  • Aged
  • Antibodies, Monoclonal / blood*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Biological Factors / therapeutic use*
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Infliximab / therapeutic use
  • Interleukin-33 / blood*
  • Male
  • Middle Aged
  • Rituximab / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Biological Factors
  • Interleukin-33
  • Rituximab
  • Abatacept
  • Infliximab
  • Adalimumab
  • tocilizumab
  • Etanercept

Associated data

  • ClinicalTrials.gov/NCT01000441